Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Instagram Outage Disrupts Thousands of U.S. Users 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
LOS ANGELES, Aug. 28, 2017 -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Ocular Therapeutix, Inc. (“Ocular” or the “Company”) (Nasdaq:OCUL) regarding possible violations of federal securities laws from May 5, 2017 through July 6, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired Ocular shares during the Class Period should contact the firm before the September 5, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet, and until a class is certified, you are not considered to be represented by an attorney. You may choose to do nothing and be an absent class member as well.
According to the Complaint, during the Class Period, Ocular made false and/or misleading statements and/or failed to disclose: that the Company’s management misled investors about DEXTENZA manufacturing issues, including that more than half of lots manufactured by Ocular contain bad product; that these manufacturing issues could endanger the approval of DEXTENZA by the FDA; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. When this information reached the public, shares of Ocular lowered in value materially, which caused investors harm according to the lawsuit.
Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles, dedicated to upholding shareholders’ rights.
This press release may constitute Attorney Advertising in certain jurisdictions under the applicable law and rules of ethics.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
